Satoshi Funakoshi

Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study

Ryosuke Morio, Takahiro Takazono, Shimpei Morimoto, Nobuyuki Ashizawa et autres

Patients on maintenance hemodialysis (HD) have impaired immune function and are at high risk of severe COVID-19; however, comparative data on immunogenicity and vaccine choice behavior between mRNA and protein subunit SARS-CoV-2 vaccines remain limited. In this observational study, 227 participants (202 …

jp (code pays fourni par la source)

Comparison of immunogenicity and efficacy of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study

Ryosuke Morio, Takahiro Takazono, Nobuyuki Ashizawa, Tatsuro Hirayama et autres

jp (code pays fourni par la source)

Frailty in Patients on Hemodialysis Is Independently Associated with Hearing Loss, Age, and Diabetes: Results from a 229-Patient Cohort

Satoshi Funakoshi, Akihiro MAEKAWA, Kenji Sawase, Jyunichiro Hashiguchi

Background: Frailty is highly prevalent among elderly patients undergoing hemodialysis (HD), yet its association with hearing loss—a common geriatric syndrome—remains largely unexplored in this population. Methods: We conducted a cross-sectional study involving 229 HD patients at a single center from November to …

jp (code pays fourni par la source)

Comparative Phosphate-Lowering Effects of Tenapanor in Combination with Different Phosphate Binders in Patients on Hemodialysis: A Prospective Pilot Study

Satoshi Funakoshi, Masatoshi Hayashida, Kenji Sawase, Jyunichiro Hashiguchi et autres

Background: Hyperphosphatemia is a well-known contributor to cardiovascular morbidity and mortality in patients receiving hemodialysis (HD). Despite the widespread use of phosphate binders, approximately 30% of Japanese HD patients fail to achieve target serum phosphate (P) levels. Tenapanor, a novel phosphate absorption …

jp (code pays fourni par la source)

Sacubitril/Valsartan Improves Glycoalbumin in Patients with Diabetes on Hemodialysis: Potential Metabolic Benefit of Angiotensin Receptor-Neprilysin Inhibition

Satoshi Funakoshi, Masatoshi Hayashida, Jyunichiro Hashiguchi, Akihiro MAEKAWA et autres

Background: Sacubitril/valsartan (Entresto), an angiotensin receptor–neprilysin inhibitor (ARNI), is known for its cardioprotective and antihypertensive effects. Recent findings suggest it may also preserve DPP-4–sensitive peptides, potentially improving insulin sensitivity. However, its metabolic impact has not been evaluated in hemodialysis patients. In this …

jp (code pays fourni par la source)

274PEstablishment of a 3D cardiomyopathy model for Duchenne muscular dystrophy using patient-derived iPS cells

Fumika Inazuka, Satoshi Funakoshi, Yuya Fujiwara, Masako Sasaki et autres

jp (code pays fourni par la source)

Prognostic value of Glasgow prognostic score in patients undergoing hemodialysis

Ryosuke Sakamoto, Kenta Torigoe, Shinichi Abe, Mineaki Kitamura et autres

INTRODUCTION: Usefulness of the Glasgow prognostic score (GPS), modified GPS (mGPS), and high-sensitivity mGPS (HS-mGPS) in the prognosis of patients undergoing hemodialysis remains unclear. This study aimed to investigate this. METHODS: The GPS, mGPS, and HS-mGPS were calculated retrospectively in 339 patients …

jp (code pays fourni par la source)

Comparison of Three HIF‒PH Inhibitors for ESA‒resistant Renal Anemia and Exploration of Treatment Response‒predicting Factors

Shuichi Sato, Masatoshi Hayashida, Toshiyuki Yano, Tomoyuki Takaki et autres

腎性貧血の治療は従来，エリスロポエチン製剤（ESA）が中心だったが，慢性炎症や鉄利用障害を背景にESA抵抗性を示す患者が一定数存在する．近年登場したHIF‒PH阻害薬は，内因性EPO産生と鉄代謝改善を促す新たな選択肢として注目されるが，長期的な有効性や使い分けは十分に検討されていない．本研究では，ESA抵抗性腎性貧血患者を対象に，ロキサデュスタット（Rox），ダプロデュスタット（Dap），エナロデュスタット（Ena）の3剤を100週間追跡し，Hbコントロール，投与量，安全性を比較した．さらに機械学習により治療反応性に影響する因子を探索した結果，治療開始前の鉄代謝，造血状態，銅代謝が重要であることが示唆された．これらを事前に把握することで，反応性の低い症例の予測と治療効果の最大化が期待される．

jp, pk (code pays fourni par la source)

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study

Emiko Otsuka, Mineaki Kitamura, Satoshi Funakoshi, Hiroshi Mukae et autres

Roxadustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, has proven efficacy in the treatment of renal anemia; however, evidence indicates that it may cause central hypothyroidism. The prevalence and reversibility of roxadustat-induced central hypothyroidism in patients undergoing hemodialysis remain unclear. Here, we retrospectively analyzed …

jp (code pays fourni par la source)

Mature cardiac tissues modeling Duchenne muscular dystrophy related cardiomyopathy

Fumika Inazuka, Satoshi Funakoshi, Yuya Fujiwara, Masako Sasaki et autres

Abstract Background The major cause of mortality in patients with Duchenne muscular dystrophy (DMD) is cardiomyopathy. This disease is caused by dystrophin gene mutations that result in the loss of dystrophin protein. Gene replacement therapies have been approved for skeletal muscle symptoms …

jp (code pays fourni par la source)

Tirzepatide Improves Glycemic Control Better than Dulagutide in Patients Undergoing Hemodialysis

Emiko Otsuka, Mineaki Kitamura, Shinichi Abe, Satoshi Funakoshi et autres

Background: Glycemic control is crucial to reduce cardiovascular events and mortality in patients with type 2 diabetes undergoing hemodialysis. On the other hand, some anti-diabetic drugs are of limited use or contraindicated in patients undergoing hemodialysis. Tirzepatide is a novel dual glucagon-like …

jp (code pays fourni par la source)

Projected Long-Term Cost Savings with Roxadustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), among Patients on Hemodialysis: Insights from a 100-Week Longitudinal Study

Satoshi Funakoshi, Jyunichiro Hashiguchi, Shinichi Abe, Kenji Sawase et autres

Background: HIF-PH inhibitors are attracting attention for their novel mechanisms of action. However, the cost of the starting dose of HIF-PH inhibitors is considerably higher than biosimilar ESA, and it may limit the use of them. Nevertheless, HIF-PH inhibitors demonstrate targeting capabilities …

jp (code pays fourni par la source)